Scholarlink

Purpose of Review <p>Medium and, rarely, large vessel vasculitis may affect the skin, and dermatologists can be instrumental in making a timely diagnosis. The purpose of this review is to present a general overview of medium and large vessel vasculitis presenting in the skin, with a focus on the latest research.</p> Recent Findings <p>Newly published studies on cutaneous polyarteritis nodosa have highlighted novel associations, such as VEXAS and DADA2. Updated classification criteria for ANCA associated vasculitis (AAV) were recently published by the American College of Rheumatology. Avacopan, mepolizumab, and benralizumab are exciting new therapies for AAV.</p> Summary <p>Much progress has been made towards the goal of a structured, evidence-based approach to cutaneous vasculitis. While work remains to be done, standardization of disease classifications and phase 3 clinical trials have paved the way for novel therapies, particularly in ANCA associated vasculitis. This review will provide an overview of medium and large vessel vasculitis for the practicing dermatologist.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Medium and Large Vessel Vasculitis, Clinical Review for the Inpatient Dermatologist

  • 期刊论文

  • 发表日期：

    2025年1月24日

查看全文
  • Evan W. Piette

摘要

Purpose of Review

Medium and, rarely, large vessel vasculitis may affect the skin, and dermatologists can be instrumental in making a timely diagnosis. The purpose of this review is to present a general overview of medium and large vessel vasculitis presenting in the skin, with a focus on the latest research.

Recent Findings

Newly published studies on cutaneous polyarteritis nodosa have highlighted novel associations, such as VEXAS and DADA2. Updated classification criteria for ANCA associated vasculitis (AAV) were recently published by the American College of Rheumatology. Avacopan, mepolizumab, and benralizumab are exciting new therapies for AAV.

Summary

Much progress has been made towards the goal of a structured, evidence-based approach to cutaneous vasculitis. While work remains to be done, standardization of disease classifications and phase 3 clinical trials have paved the way for novel therapies, particularly in ANCA associated vasculitis. This review will provide an overview of medium and large vessel vasculitis for the practicing dermatologist.